1
|
Kurahara LH, Hiraishi K, Hu Y, Koga K, Onitsuka M, Doi M, Aoyagi K, Takedatsu H, Kojima D, Fujihara Y, Jian Y, Inoue R. Activation of Myofibroblast TRPA1 by Steroids and Pirfenidone Ameliorates Fibrosis in Experimental Crohn's Disease. Cell Mol Gastroenterol Hepatol 2017; 5:299-318. [PMID: 29552620 PMCID: PMC5852292 DOI: 10.1016/j.jcmgh.2017.12.005] [Citation(s) in RCA: 36] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/02/2017] [Accepted: 12/07/2017] [Indexed: 02/08/2023]
Abstract
BACKGROUND & AIMS The transient receptor potential ankyrin 1 (TRPA1) channel is highly expressed in the intestinal lamina propria, but its contribution to gut physiology/pathophysiology is unclear. Here, we evaluated the function of myofibroblast TRPA1 channels in intestinal remodeling. METHODS An intestinal myofibroblast cell line (InMyoFibs) was stimulated by transforming growth factor-β1 to induce in vitro fibrosis. Trpa1 knockout mice were generated using the Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 (Cas9) system. A murine chronic colitis model was established by weekly intrarectal trinitrobenzene sulfonic acid (TNBS) administration. Samples from the intestines of Crohn's disease (CD) patients were used for pathologic staining and quantitative analyses. RESULTS In InMyoFibs, TRPA1 showed the highest expression among TRP family members. In TNBS chronic colitis model mice, the extents of inflammation and fibrotic changes were more prominent in TRPA1-/- knockout than in wild-type mice. One-week enema administration of prednisolone suppressed fibrotic lesions in wild-type mice, but not in TRPA1 knockout mice. Steroids and pirfenidone induced Ca2+ influx in InMyoFibs, which was antagonized by the selective TRPA1 channel blocker HC-030031. Steroids and pirfenidone counteracted transforming growth factor-β1-induced expression of heat shock protein 47, type 1 collagen, and α-smooth muscle actin, and reduced Smad-2 phosphorylation and myocardin expression in InMyoFibs. In stenotic intestinal regions of CD patients, TRPA1 expression was increased significantly. TRPA1/heat shock protein 47 double-positive cells accumulated in the stenotic intestinal regions of both CD patients and TNBS-treated mice. CONCLUSIONS TRPA1, in addition to its anti-inflammatory actions, may protect against intestinal fibrosis, thus being a novel therapeutic target for highly incurable inflammatory/fibrotic disorders.
Collapse
Key Words
- AITC, allyl isothiocyanate
- CD, Crohn’s disease
- Crohn’s Disease
- EGTA, ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid
- HSP47, heat shock protein 47
- InMyoFib, intestinal myofibroblast cell line
- Intestinal Fibrosis
- KO, knockout
- MT, Masson trichrome
- Myofibroblast
- PBS, phosphate-buffered saline
- PCR, polymerase chain reaction
- RT-PCR, reverse-transcription polymerase chain reaction
- TGF, transforming growth factor
- TNBS, trinitrobenzene sulfonic acid
- TNF, tumor necrosis factor
- TRP, transient receptor potential
- TRPA1, transient receptor potential ankyrin 1
- TRPC, transient receptor potential canonical
- Transient Receptor Potential Ankyrin 1
- WT, wild-type
- mRNA, messenger RNA
- sgRNA, single-guide RNA
- siRNA, small interfering RNA
- α-SMA, α smooth muscle actin
Collapse
Affiliation(s)
- Lin Hai Kurahara
- Department of Physiology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan,Correspondence Address correspondence to: Lin Hai Kurahara, PhD, Department of Physiology, Faculty of Medicine, Fukuoka University, Fukuoka 814-0180, Japan. fax: (81) 92-865-6032.Department of PhysiologyFaculty of MedicineFukuoka UniversityFukuoka814-0180Japan
| | - Keizo Hiraishi
- Department of Physiology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
| | - Yaopeng Hu
- Department of Physiology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
| | - Kaori Koga
- Department of Pathology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
| | - Miki Onitsuka
- Department of Pathology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
| | - Mayumi Doi
- Department of Physiology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan,Department of Clinical Pharmacology and Therapeutics, Faculty of Medicine, Oita University, Oita, Japan
| | - Kunihiko Aoyagi
- Department of Gastroenterology, Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan
| | - Hidetoshi Takedatsu
- Department of Gastroenterology and Medicine, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
| | - Daibo Kojima
- Department of Gastroenterological Surgery, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
| | - Yoshitaka Fujihara
- Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
| | - Yuwen Jian
- College of Letters and Science, University of California—Davis, Davis, California
| | - Ryuji Inoue
- Department of Physiology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
| |
Collapse
|
2
|
Chen X, Wang K. The fate of medications evaluated for ischemic stroke pharmacotherapy over the period 1995-2015. Acta Pharm Sin B 2016; 6:522-30. [PMID: 27818918 DOI: 10.1016/j.apsb.2016.06.013] [Citation(s) in RCA: 53] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2016] [Revised: 05/26/2016] [Accepted: 05/31/2016] [Indexed: 01/26/2023] Open
Abstract
Stroke is a brain damage caused by a loss of blood supply to a portion of the brain, which requires prompt and effective treatment. The current pharmacotherapy for ischemic stroke primarily relies on thrombolysis using recombinant tissue plasminogen activators (rt-PAs) to breakdown blood clots. Neuroprotective agents that inhibit excitatory neurotransmitters are also used to treat ischemic stroke but have failed to translate into clinical benefits. This poses a major challenge in biomedical research to understand what causes the progressive brain cell death after stroke and how to develop an effective pharmacotherapy for stroke. This brief review analyzes the fate of about 430 potentially useful stroke medications over the period 1995–2015 and describes in detail those that successfully reached the market. Hopefully, the information from this analysis will shed light on how future stroke research can improve stroke drug discovery.
Collapse
Key Words
- ADP, adenosine diphosphate
- AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
- ASIC1a, acid-sensing ion channel 1a
- BDNF, brain-derived neurotrophic factor
- CFDA, the China Food and Drug Administration
- CNTF, ciliary neurotrophic factor
- GDNF, glial cell line–derived neurotrophic factor
- Ion channel
- Ischemic stroke
- MHRA, Medicine and Healthcare Products Regulatory Agency
- NBP, butylphthalide/3-n-butylphthalide
- NGF, nerve growth factor
- NMDA, N-methyl-D-aspartate
- Neuroprotective agent
- Non-NMDA mechanism
- TCM, traditional Chinese medicine
- TRP, transient receptor potential
- TRPC, transient receptor potential canonical
- TRPM, transient receptor potential melastatin
- TRPV, transient receptor potential vanilloid
- Thrombosis
- Traditional Chinese medicine
- iGluRs, ionotropic glutamate receptors
- rt-Pas, recombinant tissue plasminogen activators
Collapse
|